CRP and rheumatoid arthritis: In a post hoc analysis of patients with RA receiving the TNFi adalimumab (ADA) plus MTX in two randomized controlled trials, a greater number of prior csDMARDs (> 2 vs 0–1) were associated with less improvement from baseline in Disease Activity Score in 28 joints, C-reactive protein (DAS28-4[CRP]) and Health Assessment Questionnaire-Disability Index (HAQ-DI), and lower ACR response rates at week 24 [7].